生物
多重耐药
细胞凋亡
程序性细胞死亡
蛋白激酶B
抗药性
允许的
癌症研究
癌症
表型
机制(生物学)
计算生物学
遗传学
基因
认识论
哲学
作者
Yves Pommier,Olivier Sordet,Smitha Antony,Richard L. Hayward,Kurt W. Kohn
出处
期刊:Oncogene
[Springer Nature]
日期:2004-04-12
卷期号:23 (16): 2934-2949
被引量:544
标识
DOI:10.1038/sj.onc.1207515
摘要
Intrinsic (innate) and acquired (adaptive) resistance to chemotherapy critically limits the outcome of cancer treatments. For many years, it was assumed that the interaction of a drug with its molecular target would yield a lethal lesion, and that determinants of intrinsic drug resistance should therefore be sought either at the target level (quantitative changes or/and mutations) or upstream of this interaction, in drug metabolism or drug transport mechanisms. It is now apparent that independent of the factors above, cellular responses to a molecular lesion can determine the outcome of therapy. This review will focus on programmed cell death (apoptosis) and on survival pathways (Bcl-2, Apaf-1, AKT, NF-κB) involved in multidrug resistance. We will present our molecular interaction mapping conventions to summarize the AKT and IκB/NF-κB networks. They complement the p53, Chk2 and c-Abl maps published recently. We will also introduce the 'permissive apoptosis-resistance' model for the selection of multidrug-resistant cells.
科研通智能强力驱动
Strongly Powered by AbleSci AI